Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Secukinumab in Pediatric Chronic Plaque Psoriasis
NCT03668613Phase 3Completed
- Sponsor
- Novartis
- Start
- Aug 2018
- Primary completion
- Sep 2019
- Modality
- Monoclonal Antibodies
- Countries
- 9
01
Overview
A Phase 3 trial of secukinumab in psoriasis, sponsored by Novartis. Started Aug 2018; status: completed.
02
Drugs
secukinumab
03
Conditions
psoriasis
Beyond the preview
Go deeper on NCT03668613.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03668613.